title: Modification of 24-hour growth hormone secretion after continuous subcutaneous infusion of growth hormone-releasing hormone (GHRH (1-29)NH2) in short children with low 24-hour growth hormone secretion.
abstract: Six short children with low 24-hour growth hormone (GH) secretion were treated with continuous subcutaneous infusion of GHRH (1-29)NH2 for 3 weeks using a portable infusion pump. Restoration of pulsatile GH secretion was observed in all three children treated with 40 micrograms/kg/day of GHRH, but in only one of the three children treated with 20 micrograms/kg/day. All parameters of 24-hour GH secretion increased, but in five children the magnitude of the GH response was greater on day 1 than on day 21 of GHRH treatment. This decrease was not observed in the single child who responded to a low dose of GHRH (20 micrograms/kg/day); on the contrary, the response in this patient was greater after 21 days of GHRH treatment. Plasma levels of GHRH (1-29)NH2 were significantly higher on day 21 than on day 1 of treatment, suggesting altered pharmacokinetics over time. The effect of GHRH treatment on growth could not be determined because of the short duration of the study, but the data obtained on 24-hour GH secretion and GHRH metabolism suggest that a long-acting analogue of GHRH could be useful for the treatment of GH deficient or insufficient children.
authors.affiliation: Department of Paediatric Endocrinology, CHU Rangueil, Toulouse, France.
authors.forename: M T
authors.initials: MT
authors.lastname: Tauber
authors.forename: C
authors.initials: C
authors.lastname: Pienkowski
authors.forename: F
authors.initials: F
authors.lastname: Landier
authors.forename: R
authors.initials: R
authors.lastname: Gunnarsson
authors.forename: P
authors.initials: P
authors.lastname: Rochiccioli
mesh_terms: D000293:Adolescent; D002648:Child; D002940:Circadian Rhythm; D004305:Dose-Response Relationship, Drug; D005260:Female; D006130:Growth Disorders / Q000188:drug therapy*; D013006:Growth Hormone / Q000172:deficiency / Q000378:metabolism*; D013007:Growth Hormone-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010446:Peptide Fragments / Q000627:therapeutic use*; D017337:Sermorelin; D013997:Time Factors
chemical_list: D010446:Peptide Fragments; D017337:Sermorelin; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone